Nuvalent
potential best in class profile for alk opportunity to both move up the treatment paradigm grow the market with deep durable responses no clear standard of care soc current soc compound mutations disease single mutations disease current soc of disease demonstrated activity where current available therapies have failed opportunity to differentiate with deep durable responses and clinical activity observed in heavily patients who likely exhausted all available therapies with single and compound mutations with history of metastasis including intracranial responses sparing clinical activity observed in patients with single and compound resistance mutations clinical activity observed in patients who are naive favorable overall preliminary safety consistent with avoiding related head to head clinical studies comparing with currently approved or investigational therapies have not been conducted sources sales and forecasts accessed and lung cancer jama shaw and no peters shaw lancet jack cancer res lin package inserts and | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
April 2024
Slide
25 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
February 2024
potential best in class profile for alk opportunity to both move up the treatment paradigm grow the market with deep durable responses no clear standard of care soc current soc compound mutations disease single mutations disease current soc of disease demonstrated activity where current available therapies have failed opportunity to differentiate with deep durable responses and clinical activity observed in heavily patients who likely exhausted all available therapies with single and compound mutations with history of metastasis including intracranial responses sparing clinical activity observed in patients with single and compound resistance mutations clinical activity observed in patients who are naive favorable overall preliminary safety consistent with avoiding related head to head clinical studies comparing with currently approved or investigational therapies have not been conducted sources sales and forecasts accessed and lung cancer jama shaw and no peters shaw lancet jack cancer res lin package inserts and | Nuvalent
Investor Presentation
January 2024
potential best in class profile for alk opportunity to both move up the treatment paradigm grow the market with deep durable responses no clear standard of care soc current soc compound mutations disease single mutations disease current soc of disease demonstrated activity where current available therapies have failed opportunity to differentiate with deep durable responses and clinical activity observed in heavily patients who likely exhausted all available therapies with single and compound mutations with history of metastasis including intracranial responses sparing clinical activity observed in patients with single and compound resistance mutations clinical activity observed in patients who are naive favorable overall preliminary safety consistent with avoiding related head to head clinical studies comparing with currently approved or investigational therapies have not been conducted sources sales and forecasts accessed and lung cancer jama shaw and no peters shaw lancet jack cancer res lin package inserts and | Nuvalent
Investor Presentation
January 2024
potential best in class profile for alk opportunity to both move up the treatment paradigm grow the market with deep durable responses no clear standard of care soc current soc compound mutations disease single mutations disease current soc of disease demonstrated activity where current available therapies have failed opportunity to differentiate with deep durable responses and clinical activity observed in heavily patients who likely exhausted all available therapies with single and compound mutations with history of metastasis including intracranial responses sparing clinical activity observed in patients with single and compound resistance mutations clinical activity observed in patients who are naive favorable overall preliminary safety consistent with avoiding related head to head clinical studies comparing with currently approved or investigational therapies have not been conducted sources sales and forecasts accessed and lung cancer jama shaw and no peters shaw lancet jack cancer res lin package inserts and | Nuvalent
Related slides by other companies
Kymera
Investor Presentation
December 2023
emerging clinical data support therapeutic hypothesis for degrader | Kymera
Taysha
IPO
September 2020
deep pipeline of gene therapies targeting neurodegenerative diseases | Taysha
Taysha
IPO
September 2020
deep pipeline of gene therapies targeting disorders | Taysha
Taysha
IPO
September 2020
deep pipeline of gene therapies targeting | Taysha
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io